There was a high rate of prescription of patients on insulin (CKD stage 3, 9.3%; stage 4, 18.0%; stage 5, 13.6%, P for trend <0.001) and using an erythropoiesis-stimulating agent (ESA) in late-stage CKD patients (CKD stage 3, 2.2%; stage 4, 12.9%; stage 5, 47.9%, P for trend <0.001). The gene discussed is INS; the disease is chronic kidney disease.